HotHouse Therapeutics is featured in C&EN, the leading authority in global chemistry news by the American Chemical Society

We were delighted to be interviewed by Max Barnhart of C&EN about our coming-out-of-stealth story.

“The company says its AI and synthetic biology platform can produce compounds not possible with traditional synthesis. HotHouse Therapeutics has emerged from stealth with a little over $3 million in preseed funding. The start-up, based in Norwich, England, mixes artificial intelligence and synthetic biology to reprogram plant biosynthetic pathways to create new molecules.”

Read the article in full here: HotHouse launches to remix plant compound biosynthesis for pharma